ARTICLE | Company News
Roche (SIX:ROG; OTCQX:RHHBY) disclosed in its Thursday earnings report that it will discontinue development of RG6047 (GDC-0927). The selective estrogen receptor degrader was in a Phase I trial to treat ER-positive, HER2-negative metastatic breast cancer.
Roche gained the candidate when its Genentech Inc. unit acquired Seragon Pharmaceuticals Inc. in 2014. This is the second SERD candidate from Seragon that Roche has discontinued; in April, the pharma halted development of RG6046 (see BioCentury Extra, April 27, 2017). ...